Pivekimab, referred to as IBAT®, is one innovative genetically engineered targeted immunoglobulin engineered for directly bind to while block IL-6, the key cytokine implicated with multiple pathogenic responses https://ztndz.com/story28498741/pivekimab-the-deep-investigation-into-the-engineered-targeted-antibody